RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine

about

RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine

Item

http://www.wikidata.org/entity/Q57162471

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@en

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@nl

type

Item

label

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@en

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@nl

prefLabel

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@en

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@nl

P1476

RAS-expanded Mutations and HER ...... New Step of Precision Medicine

@en

P2093

Anna M Valentini

http://www.w3.org/2001/XMLSchema#string

Elisabetta Cavalcanti

http://www.w3.org/2001/XMLSchema#string

Maria L Caruso

http://www.w3.org/2001/XMLSchema#string

Marianna Di Maggio

http://www.w3.org/2001/XMLSchema#string

P2860

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer

New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

P304

539-544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAI.0000000000000475

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30199395

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

medical laboratory technology

Cho͘-chit-ha̍k

P932

6135466

http://www.w3.org/2001/XMLSchema#string